tetano
Editor, Senior Moderator
J Med Virol
. 2021 Jan 19.
doi: 10.1002/jmv.26810. Online ahead of print.
Follow-up of SARS-CoV-2 Positive Subgroup from the Asymptomatic novel CORonavirus iNfection (ACORN) Study
Kristin J Meyers[SUP] 1 [/SUP], Brian Dillman[SUP] 1 [/SUP], Charles Williams[SUP] 1 [/SUP], Jianfei Jiang[SUP] 1 [/SUP], Nancy Clifford[SUP] 1 [/SUP], Jennifer L Miller[SUP] 1 [/SUP], Meghan E Jones[SUP] 1 [/SUP], Iris A Goetz[SUP] 1 [/SUP], Fady T Botros[SUP] 1 [/SUP], Jack Knorr[SUP] 1 [/SUP], David H Manner[SUP] 1 [/SUP], Brad Woodward[SUP] 1 [/SUP]
Affiliations
Abstract
A nested longitudinal study within the Asymptomatic novel CORonavirus iNfection (ACORN) study followed participants with positive nasopharyngeal swab to query for development of symptoms and assess duration of positive RT-PCR test results. Of the 91 participants initially testing positive, 86 participated in follow-up approximately 14 days after study enrollment; of those 86 participants, 19 (22.1%) developed at least one symptom at any time after the initial positive SARS-CoV-2 test result. The median number of days to symptom development after their initial positive test result was 6 (range 1-29 days). No participants reported a SARS-CoV-2-related hospitalization. The most frequently reported symptoms were fatigue or muscle aches (10.5%), headache (9.3%), fever (5.8%), and shortness of breath (5.8%). Of the 78 participants who submitted a nasopharyngeal swab for repeat RT-PCR testing, 17 (21.8%) remained positive at Day 14, 4 of which continued to test positive at Day 28. These findings reinforce the probable role of silent SARS-CoV-2 infections in community transmission, and that reliance on symptom development will miss a large proportion of infections. Broad testing programs not limited to individuals presenting with symptoms are critical for identifying persons with SARS-CoV-2 infection and ultimately slowing transmission. This article is protected by copyright. All rights reserved.
Keywords: Asymptomatic infections; SARS-CoV-2; viral load.
. 2021 Jan 19.
doi: 10.1002/jmv.26810. Online ahead of print.
Follow-up of SARS-CoV-2 Positive Subgroup from the Asymptomatic novel CORonavirus iNfection (ACORN) Study
Kristin J Meyers[SUP] 1 [/SUP], Brian Dillman[SUP] 1 [/SUP], Charles Williams[SUP] 1 [/SUP], Jianfei Jiang[SUP] 1 [/SUP], Nancy Clifford[SUP] 1 [/SUP], Jennifer L Miller[SUP] 1 [/SUP], Meghan E Jones[SUP] 1 [/SUP], Iris A Goetz[SUP] 1 [/SUP], Fady T Botros[SUP] 1 [/SUP], Jack Knorr[SUP] 1 [/SUP], David H Manner[SUP] 1 [/SUP], Brad Woodward[SUP] 1 [/SUP]
Affiliations
- PMID: 33463731
- DOI: 10.1002/jmv.26810
Abstract
A nested longitudinal study within the Asymptomatic novel CORonavirus iNfection (ACORN) study followed participants with positive nasopharyngeal swab to query for development of symptoms and assess duration of positive RT-PCR test results. Of the 91 participants initially testing positive, 86 participated in follow-up approximately 14 days after study enrollment; of those 86 participants, 19 (22.1%) developed at least one symptom at any time after the initial positive SARS-CoV-2 test result. The median number of days to symptom development after their initial positive test result was 6 (range 1-29 days). No participants reported a SARS-CoV-2-related hospitalization. The most frequently reported symptoms were fatigue or muscle aches (10.5%), headache (9.3%), fever (5.8%), and shortness of breath (5.8%). Of the 78 participants who submitted a nasopharyngeal swab for repeat RT-PCR testing, 17 (21.8%) remained positive at Day 14, 4 of which continued to test positive at Day 28. These findings reinforce the probable role of silent SARS-CoV-2 infections in community transmission, and that reliance on symptom development will miss a large proportion of infections. Broad testing programs not limited to individuals presenting with symptoms are critical for identifying persons with SARS-CoV-2 infection and ultimately slowing transmission. This article is protected by copyright. All rights reserved.
Keywords: Asymptomatic infections; SARS-CoV-2; viral load.